Prebiotic Effect on Metabolites in Crohn's Disease
Not Applicable
Completed
- Conditions
- Crohn Disease
- Registration Number
- NCT01487759
- Lead Sponsor
- KU Leuven
- Brief Summary
The purpose of this study is to investigate the influence of the prebiotic oligofructose enriched inulin on the metabolite pattern in Crohn's disease patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 67
Inclusion Criteria
- crohn's disease
Exclusion Criteria
- severe crohn's disease (harvey bradshaw index >12)
- pregnancy
- history of colectomy
- use of antibiotics 4-wks before start of the study
- use of sulfapyridine
- use of commercially available prebiotics and probiotics
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link oligofructose-enriched inulin to metabolite changes in Crohn's disease patients?
How does oligofructose-enriched inulin compare to anti-TNF therapies in modulating gut microbiota metabolites for Crohn's disease?
Which biomarkers correlate with response to prebiotic metabolite modulation in NCT01487759 Crohn's disease trials?
What adverse events are associated with oligofructose-enriched inulin in inflammatory bowel disease, and how are they managed?
Are there synergistic effects of combining oligofructose-enriched inulin with probiotics or immunomodulators in Crohn's disease treatment?
Trial Locations
- Locations (1)
KULeuven
🇧🇪Leuven, Belgium
KULeuven🇧🇪Leuven, Belgium